SRPT — Sarepta Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.10bn
- $1.99bn
- $2.20bn
Annual income statement for Sarepta Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 702 | 933 | 1,243 | 1,902 | 2,198 |
| Cost of Revenue | |||||
| Gross Profit | 605 | 793 | 1,093 | 1,583 | 1,524 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,064 | 1,597 | 1,827 | 1,684 | 2,881 |
| Operating Profit | -362 | -664 | -583 | 218 | -683 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -419 | -690 | -520 | 261 | -702 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -419 | -703 | -536 | 235 | -713 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -419 | -703 | -536 | 235 | -713 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -419 | -703 | -536 | 252 | -713 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.85 | -7.08 | -3.58 | 2.34 | -5.89 |